ImmunomeInc Net Receivables vs Long Term Debt Analysis

IMNM Stock

USD 14.94 0.23 1.56%

ImmunomeInc financial indicator trend analysis is infinitely more than just investigating ImmunomeInc recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ImmunomeInc is a good investment. Please check the relationship between ImmunomeInc Net Receivables and its Long Term Debt accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImmunomeInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

To learn how to invest in ImmunomeInc Stock, please use our How to Invest in ImmunomeInc guide.

Net Receivables vs Long Term Debt

Net Receivables vs Long Term Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ImmunomeInc Net Receivables account and Long Term Debt. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between ImmunomeInc's Net Receivables and Long Term Debt is -0.19. Overlapping area represents the amount of variation of Net Receivables that can explain the historical movement of Long Term Debt in the same time period over historical financial statements of ImmunomeInc, assuming nothing else is changed. The correlation between historical values of ImmunomeInc's Net Receivables and Long Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Receivables of ImmunomeInc are associated (or correlated) with its Long Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Long Term Debt has no effect on the direction of Net Receivables i.e., ImmunomeInc's Net Receivables and Long Term Debt go up and down completely randomly.

Correlation Coefficient

-0.19

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Net Receivables

Long Term Debt

Long-term debt is a debt that ImmunomeInc has held for over one year. Long-term debt appears on ImmunomeInc balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on ImmunomeInc balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.

Most indicators from ImmunomeInc's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ImmunomeInc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImmunomeInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

To learn how to invest in ImmunomeInc Stock, please use our How to Invest in ImmunomeInc guide.At this time, ImmunomeInc's Selling General Administrative is very stable compared to the past year. As of the 1st of June 2024, Enterprise Value is likely to grow to about 121.1 M, while Issuance Of Capital Stock is likely to drop about 29.1 K.

	2021	2023	2024 (projected)
Depreciation And Amortization	503K	728K	689.9K
Interest Income	5K	2.7M	2.9M

Depreciation And Amortization Interest Income

ImmunomeInc fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Lease Obligations	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Short Long Term Debt
Total Assets		0.03	0.78	0.98	0.98	-0.69	0.61	0.33	-0.99	-0.96	0.77	0.99	0.36	-0.62	-0.67	-0.64	1.0	0.79	-0.62	0.76	0.76	0.98	-0.37	0.98	0.94	0.67
Short Long Term Debt Total	0.03		-0.24	0.0	-0.09	0.25	-0.51	0.91	0.06	0.03	-0.32	-0.06	0.9	-0.18	-0.47	0.6	0.03	-0.05	0.47	0.55	-0.3	-0.06	0.63	-0.09	0.26	-0.36
Other Current Liab	0.78	-0.24		0.83	0.83	-0.62	0.78	0.04	-0.84	-0.83	0.99	0.81	0.1	-0.15	-0.13	-0.74	0.77	0.95	-0.79	0.41	0.94	0.82	-0.5	0.82	0.66	0.88
Total Current Liabilities	0.98	0.0	0.83		0.96	-0.62	0.58	0.3	-0.96	-0.98	0.81	0.97	0.34	-0.51	-0.57	-0.63	0.98	0.85	-0.61	0.78	0.76	0.99	-0.34	0.96	0.93	0.65
Total Stockholder Equity	0.98	-0.09	0.83	0.96		-0.8	0.75	0.21	-0.99	-0.95	0.84	0.99	0.23	-0.56	-0.59	-0.7	0.98	0.79	-0.76	0.65	0.83	0.98	-0.53	1.0	0.87	0.78
Other Liab	-0.69	0.25	-0.62	-0.62	-0.8		-0.89	0.06	0.76	0.64	-0.68	-0.75	0.08	0.39	0.4	0.58	-0.69	-0.49	0.92	-0.21	-0.7	-0.72	0.86	-0.8	-0.45	-0.84
Net Tangible Assets	0.61	-0.51	0.78	0.58	0.75	-0.89		-0.31	-0.72	-0.58	0.84	0.7	-0.3	-0.18	-0.1	-0.74	0.61	0.59	-0.97	0.01	0.88	0.65	-0.88	0.75	0.38	0.93
Property Plant And Equipment Net	0.33	0.91	0.04	0.3	0.21	0.06	-0.31		-0.25	-0.29	-0.04	0.25	0.99	-0.48	-0.69	0.22	0.34	0.26	0.28	0.69	-0.04	0.25	0.55	0.21	0.49	-0.08
Net Debt	-0.99	0.06	-0.84	-0.96	-0.99	0.76	-0.72	-0.25		0.95	-0.84	-1.0	-0.27	0.59	0.61	0.71	-0.99	-0.81	0.72	-0.66	-0.84	-0.98	0.47	-0.99	-0.89	-0.76
Retained Earnings	-0.96	0.03	-0.83	-0.98	-0.95	0.64	-0.58	-0.29	0.95		-0.83	-0.95	-0.33	0.52	0.56	0.68	-0.96	-0.88	0.65	-0.73	-0.72	-0.99	0.37	-0.95	-0.86	-0.71
Accounts Payable	0.77	-0.32	0.99	0.81	0.84	-0.68	0.84	-0.04	-0.84	-0.83		0.82	0.02	-0.15	-0.12	-0.77	0.77	0.93	-0.85	0.35	0.94	0.83	-0.59	0.84	0.62	0.91
Cash	0.99	-0.06	0.81	0.97	0.99	-0.75	0.7	0.25	-1.0	-0.95	0.82		0.27	-0.6	-0.63	-0.69	0.99	0.79	-0.7	0.68	0.82	0.98	-0.46	0.99	0.9	0.73
Non Current Assets Total	0.36	0.9	0.1	0.34	0.23	0.08	-0.3	0.99	-0.27	-0.33	0.02	0.27		-0.42	-0.64	0.22	0.36	0.33	0.26	0.73	-0.01	0.28	0.55	0.23	0.53	-0.07
Non Currrent Assets Other	-0.62	-0.18	-0.15	-0.51	-0.56	0.39	-0.18	-0.48	0.59	0.52	-0.15	-0.6	-0.42		0.92	0.47	-0.63	-0.23	0.12	-0.45	-0.22	-0.55	-0.01	-0.56	-0.57	-0.24
Other Assets	-0.67	-0.47	-0.13	-0.57	-0.59	0.4	-0.1	-0.69	0.61	0.56	-0.12	-0.63	-0.64	0.92		0.21	-0.68	-0.24	0.08	-0.68	-0.18	-0.59	-0.08	-0.6	-0.69	-0.16
Long Term Debt	-0.64	0.6	-0.74	-0.63	-0.7	0.58	-0.74	0.22	0.71	0.68	-0.77	-0.69	0.22	0.47	0.21		-0.64	-0.67	0.69	-0.06	-0.74	-0.69	0.53	-0.7	-0.41	-0.79
Cash And Short Term Investments	1.0	0.03	0.77	0.98	0.98	-0.69	0.61	0.34	-0.99	-0.96	0.77	0.99	0.36	-0.63	-0.68	-0.64		0.79	-0.62	0.76	0.76	0.98	-0.36	0.98	0.94	0.66
Common Stock Shares Outstanding	0.79	-0.05	0.95	0.85	0.79	-0.49	0.59	0.26	-0.81	-0.88	0.93	0.79	0.33	-0.23	-0.24	-0.67	0.79		-0.63	0.56	0.8	0.84	-0.29	0.79	0.7	0.78
Non Current Liabilities Total	-0.62	0.47	-0.79	-0.61	-0.76	0.92	-0.97	0.28	0.72	0.65	-0.85	-0.7	0.26	0.12	0.08	0.69	-0.62	-0.63		-0.08	-0.82	-0.69	0.91	-0.76	-0.37	-0.94
Capital Lease Obligations	0.76	0.55	0.41	0.78	0.65	-0.21	0.01	0.69	-0.66	-0.73	0.35	0.68	0.73	-0.45	-0.68	-0.06	0.76	0.56	-0.08		0.3	0.71	0.17	0.65	0.89	0.13
Other Current Assets	0.76	-0.3	0.94	0.76	0.83	-0.7	0.88	-0.04	-0.84	-0.72	0.94	0.82	-0.01	-0.22	-0.18	-0.74	0.76	0.8	-0.82	0.3		0.77	-0.58	0.83	0.65	0.87
Other Stockholder Equity	0.98	-0.06	0.82	0.99	0.98	-0.72	0.65	0.25	-0.98	-0.99	0.83	0.98	0.28	-0.55	-0.59	-0.69	0.98	0.84	-0.69	0.71	0.77		-0.45	0.98	0.88	0.73
Total Liab	-0.37	0.63	-0.5	-0.34	-0.53	0.86	-0.88	0.55	0.47	0.37	-0.59	-0.46	0.55	-0.01	-0.08	0.53	-0.36	-0.29	0.91	0.17	-0.58	-0.45		-0.53	-0.09	-0.74
Net Invested Capital	0.98	-0.09	0.82	0.96	1.0	-0.8	0.75	0.21	-0.99	-0.95	0.84	0.99	0.23	-0.56	-0.6	-0.7	0.98	0.79	-0.76	0.65	0.83	0.98	-0.53		0.87	0.78
Property Plant And Equipment Gross	0.94	0.26	0.66	0.93	0.87	-0.45	0.38	0.49	-0.89	-0.86	0.62	0.9	0.53	-0.57	-0.69	-0.41	0.94	0.7	-0.37	0.89	0.65	0.88	-0.09	0.87		0.42
Short Long Term Debt	0.67	-0.36	0.88	0.65	0.78	-0.84	0.93	-0.08	-0.76	-0.71	0.91	0.73	-0.07	-0.24	-0.16	-0.79	0.66	0.78	-0.94	0.13	0.87	0.73	-0.74	0.78	0.42

Click cells to compare fundamentals

ImmunomeInc Account Relationship Matchups

ImmunomeInc fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	5.1M	44.5M	57.9M	24.0M	148.5M	156.0M
Short Long Term Debt Total	564K	613K	317K	293K	1.7M	845.7K
Other Current Liab	666K	1.4M	6.7M	4.6M	7.7M	3.9M
Total Current Liabilities	1.7M	3.0M	9.7M	7.3M	21.8M	22.9M
Total Stockholder Equity	(35.6M)	41.3M	48.2M	16.7M	119.9M	125.9M
Net Tangible Assets	(35.6M)	41.3M	48.2M	16.7M	19.2M	10.0M
Property Plant And Equipment Net	1.7M	1.5M	855K	965K	3.6M	2.0M
Net Debt	(2.0M)	(39.2M)	(48.9M)	(20.0M)	(97.0M)	(92.2M)
Retained Earnings	(36.6M)	(54.4M)	(79.1M)	(116.0M)	(222.8M)	(211.7M)
Accounts Payable	548K	1.2M	3.1M	2.4M	3.3M	2.0M
Cash	2.5M	39.8M	49.2M	20.3M	98.7M	103.6M
Non Current Assets Total	1.9M	1.6M	1.3M	1.4M	3.8M	2.3M
Cash And Short Term Investments	2.5M	39.8M	49.2M	20.3M	138.1M	145.0M
Common Stock Shares Outstanding	5.7M	3.4M	11.5M	12.1M	19.8M	10.5M
Liabilities And Stockholders Equity	5.1M	44.5M	57.9M	24.0M	148.5M	156.0M
Non Current Liabilities Total	39.0M	142K	12K	62K	6.8M	9.9M
Capital Lease Obligations	239K	0.0	317K	293K	1.7M	1.7M
Other Current Assets	579K	3.1M	7.4M	2.3M	6.3M	3.7M
Other Stockholder Equity	927K	95.7M	127.3M	132.7M	342.7M	359.8M
Total Liab	40.7M	3.2M	9.7M	7.4M	28.7M	15.9M
Net Invested Capital	(35.3M)	42.0M	48.2M	16.7M	119.9M	125.9M
Property Plant And Equipment Gross	1.7M	1.5M	3.9M	681K	7.5M	7.9M
Total Current Assets	3.1M	42.9M	56.6M	22.6M	144.7M	151.9M
Accumulated Other Comprehensive Income	(38.9M)	(44.5M)	(57.9M)	0.0	22K	23.1K
Net Working Capital	1.5M	39.9M	46.9M	15.3M	122.9M	129.0M
Short Term Debt	451K	479K	317K	293K	310K	328.3K
Property Plant Equipment	1.7M	1.5M	855K	681K	612.9K	1.1M

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as ImmunomeInc using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations

Fix portfolios for free

When determining whether ImmunomeInc is a strong investment it is important to analyze ImmunomeInc's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ImmunomeInc's future performance. For an informed investment choice regarding ImmunomeInc Stock, refer to the following important reports:

How To Invest In ImmunomeInc

Details

Is ImmunomeInc Stock a good investment?

Details

What is ImmunomeInc's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImmunomeInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

To learn how to invest in ImmunomeInc Stock, please use our How to Invest in ImmunomeInc guide.

You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.

Complementary Tools for ImmunomeInc Stock analysis

When running ImmunomeInc's price analysis, check to measure ImmunomeInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ImmunomeInc is operating at the current time. Most of ImmunomeInc's value examination focuses on studying past and present price action to predict the probability of ImmunomeInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ImmunomeInc's price. Additionally, you may evaluate how the addition of ImmunomeInc to your portfolios can decrease your overall portfolio volatility.

	Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios
	Risk-Return Analysis View associations between returns expected from investment and the risk you assume
	Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments
	Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
	Economic Indicators Top statistical indicators that provide insights into how an economy is performing
	Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas

Is ImmunomeInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ImmunomeInc. If investors know ImmunomeInc will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ImmunomeInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(17.58)

Revenue Per Share

0.427

Quarterly Revenue Growth

(0.56)

Return On Assets

(0.15)

Return On Equity

(1.55)

The market value of ImmunomeInc is measured differently than its book value, which is the value of ImmunomeInc that is recorded on the company's balance sheet. Investors also form their own opinion of ImmunomeInc's value that differs from its market value or its book value, called intrinsic value, which is ImmunomeInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ImmunomeInc's market value can be influenced by many factors that don't directly affect ImmunomeInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between ImmunomeInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if ImmunomeInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ImmunomeInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

ImmunomeInc Net Receivables vs Long Term Debt Analysis

Net Receivables vs Long Term Debt

Net Receivables vs Long Term Debt Correlation Analysis

Correlation Coefficient

Net Receivables

Long Term Debt

ImmunomeInc fundamental ratios Correlations

ImmunomeInc Account Relationship Matchups

High Positive Relationship

High Negative Relationship

ImmunomeInc fundamental ratios Accounts

Becoming a Better Investor with Macroaxis

Build Optimal Portfolios

Align your risk with return expectations

Complementary Tools for ImmunomeInc Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Stockholder Equity
Cash	+ 0.99	Total Assets
Accounts Payable	+ 0.99	Other Current Liab
Other Stockholder Equity	+ 0.99	Total Current Liabilities
Cash	+ 0.99	Total Stockholder Equity

Cash	- 1.0	Net Debt
Other Stockholder Equity	- 0.99	Retained Earnings
Net Invested Capital	- 0.99	Net Debt
Cash And Short Term Investments	- 0.99	Net Debt
Net Debt	- 0.99	Total Stockholder Equity
Net Debt	- 0.99	Total Assets